Clinical Outcomes With Dabrafenib Plus Trametinib in a Clinical Trial Versus Real-World Standard of Care in Patients With <i>BRAF</i>-Mutated Advanced NSCLC.

OS In the first-line setting, the HR for death was 0.65 (95% CI: 0.39–1.1, p = 0.11) with first-line dab-tram versus RW PBC in the unweighted analysis; however, the risk reduction did not reach statistical significance at the 0.05 level.

also in 111,027 other papers